Renal Cancer - Results from #5320

Outcomes and Drug Costs of Sunitinib Regimens for Metastatic Renal Cell Carcinoma: A Provincial Population-Based Study March 7, 2017

Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era March 7, 2017

Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma March 7, 2017

Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib March 6, 2017

Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor March 6, 2017

Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities? March 3, 2017

The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: A review March 3, 2017

FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis March 2, 2017

Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions March 2, 2017

PD-L1 Studies Across Tumor Types, its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors March 2, 2017

Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality? March 1, 2017

Nivolumab induced myxedema crisis March 1, 2017

[Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives] March 1, 2017

Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data February 20, 2017

Impact of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy February 20, 2017

Differences in Age-distribution, Oncological Diagnoses and Stage in Roma and Non-Roma Cancer Patients Registered at the Outpatient Oncology Department Poprad in 2014 and 2015 - a Retrospective Study February 17, 2017

Differences in the frequencies of HLA-class I and II alleles between German patients with renal cell carcinoma and healthy controls February 17, 2017

Pretreatment Serum Prealbumin as an Independent Prognostic Indicator in Patients With Metastatic Renal Cell Carcinoma Using Tyrosine Kinase Inhibitors as First-Line Target Therapy February 16, 2017

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing February 15, 2017

A prospective, multicenter analysis of pseudocapsule characteristics: Do all stages of renal cell carcinoma have complete pseudocapsules? February 15, 2017

Page 267 of 456